Completeness and accuracy of registration of ovarian cancer in the cancer registry of Norway

Completeness of reporting and accuracy of the diagnosis of ovarian cancer from one health region in Norway to the Cancer Registry were examined. Data kept by the Cancer Registry were evaluated against discharge diagnosis data from all 8 hospitals in the health region during the period of 1987-1996. The assessment of the accuracy of the diagnosis recorded in the Cancer Registry was based on review of all medical records in the hospital setting and on slide review of all histologic diagnoses. The overall completeness of reporting ovarian cancer to the Cancer Registry was 99.6%. The organ specific completeness of registration of histologic verified ovarian cancer within the Cancer Registry was 95.3%; 0.9% was erroneously coded and 3.5% had their diagnosis changed to ovarian cancer at re-evaluation. Of all ovarian cancer cases registered at the Cancer Registry, 91% had a primary histologic diagnosis. Among 591 cases identified with a histologic diagnosis in the Cancer Registry, the accuracy of the diagnosis was estimated at 92%. Coding errors were found in 2% of these cases, while in 6% of the cases it was not possible to reproduce the original diagnosis of ovarian cancer at re-evaluation. In order to provide data of high quality for cancer surveillance a cancer registry needs several data providers, such as histopathologic laboratory reports and clinical reports. In addition, assessment of reported data through stringent quality assurance procedures within the registry are necessary for reaching a nearly 100% completeness of registration as found for ovarian cancer in the Cancer Registry of Norway.     

Ascertainment of cancer in longitudinal research: The concordance between the Rotterdam Study and the Netherlands Cancer Registry

Complete and accurate registration of cancer is needed to provide reliable data on cancer incidence and to investigate aetiology. Such data can be derived from national cancer registries, but also from large population-based cohort studies. Yet, the concordance and discordance between these two data sources remain unknown. We evaluated completeness and accuracy of cancer registration by studying the concordance between the population-based Rotterdam Study (RS) and the Netherlands Cancer Registry (NCR) between 1989 and 2012 using the independent case ascertainment method. We compared all incident cancers in participants of the RS (aged ≥45 years) to registered cancers in the NCR in the same persons based on the date of diagnosis and the International Classification of Diseases (ICD) code. In total, 2,977 unique incident cancers among 2,685 persons were registered. Two hundred eighty-eight cancers (9.7%) were coded by the RS that were not present in the NCR. These were mostly nonpathology-confirmed lung and haematological cancers. Furthermore, 116 cancers were coded by the NCR, but not by the RS (3.9%), of which 20.7% were breast cancers. Regarding pathology-confirmed cancer diagnoses, completeness was >95% in both registries. Eighty per cent of the cancers registered in both registries were coded with the same date of diagnosis and ICD code. Of the remaining cancers, 344 (14.5%) were misclassified with regard to date of diagnosis and 72 (3.0%) with regard to ICD code. Our findings indicate that multiple sources on cancer are complementary and should be combined to ensure reliable data on cancer incidence.     

Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

PURPOSE: To analyze the age-related enrollment of cancer patients onto registration trials of new drugs or new indications approved by the US Food and Drug Administration from 1995 to 2002. PATIENTS AND METHODS: This study involved retrospective analyses of demographic data of cancer patients enrolled onto registration trials. The data on 28,766 cancer patients from 55 registration trials were analyzed according to age distributions of > or = 65, > or = 70, and > or = 75 years. The rates of enrollment in each age group for each cancer were compared with the corresponding rates in the US cancer population. The age distributions of the US cancer population were derived from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute for the period 1995 to 1999 based on the 2000 US Census. RESULTS: The proportions of the overall patient populations aged > or = 65, > or = 70, and > or = 75 years were 36%, 20%, and 9% compared with 60%, 46%, and 31%, respectively, in the US cancer population. Statistically significant under-representation of the elderly (P < .001) was noted in registration trials for all cancer treatment except for breast cancer hormonal therapies. Patients aged > or = 70 years accounted for most of the under-representation. CONCLUSION: Elderly were under-represented in the registration trials of new cancer therapies. Various strategies may be needed to evaluate cancer therapies for the elderly in prospective clinical trials and to improve cancer care in the elderly population.     

The incidences and mortalities of major cancers in China, 2009

In 2012, the National Central Cancer Registry (NCCR) of China collected cancer registration information for the year 2009 from local cancer registries and analyzed it to describe the incidences and mortalities of cancers in China. Based on the data quality criteria from NCCR, data from 104 registries covering 85,470,522 people (57,489,009 in urban areas and 27,981,513 in rural areas) were checked and evaluated. The data from 72 registries were qualified and accepted for the cancer registry annual report in 2012. The total cancer incident cases and cancer deaths were 244,366 and 154,310, respectively. The morphologically verified cases accounted for 67.23%, and 3.14% of the incident cases only had information from death certifications. The crude incidence in the Chinese cancer registration areas was 285.91/ 100,000 (317.97/100,000 in males and 253.09/100,000 in females). The age-standardized rates for incidences based on the Chinese standard population (ASRIC) and the world standard population (ASRIW) were 146.87/100,000 and 191.72/100,000, respectively, with a cumulative incidence of 22.08%. The cancer mortality in the Chinese cancer registration areas was 180.54/100,000 (224.20/100,000 in males and 135.85/100,000 in females). The age-standardized rates for mortalities based on the Chinese standard population (ASRMC) and the world standard population (ASRMW) were 85.06/100,000 and 115.65/100,000, respectively, and the cumulative mortality was 12.94% . Lung cancer, gastric cancer, colorectal cancer, liver cancer, esophageal cancer, pancreatic cancer, encephaloma, lymphoma, female breast cancer, and cervical cancer were the most common cancers, accounting for 75% of all cancer cases. Lung cancer, gastric cancer, liver cancer, esophageal cancer, colorectal cancer, pancreatic cancer, breast cancer, encephaloma, leukemia, and lymphoma accounted for 80% of all cancer deaths. The cancer registration's population coverage has been increasing, and its data quality is improving. As the basis of the cancer control program, the cancer registry plays an important role in directing anticancer strategies in the medium and long term. Because cancer burdens are different in urban and rural areas in China, prevention and control efforts should be based on practical situations.     

中国肿瘤登记情况调查结果初步分析

经全国肿瘤登记中心调查:截至到2002年10月,我国大陆31个省(自治区、直辖市)中有20个开展了肿瘤登记工作,覆盖人口计7527万,面积12.93万平方公里,分别占全国5.96%和1.38%.全国现有肿瘤登记处48个,93.8%采用医院住院病历资料,81.2%采用门诊资料,89.6%采用病理报告资料,91.7%采用死亡证明书资料;100%肿瘤登记处有专业技术人员;80%采用国际疾病分类系统(ICD-9或ICD-10)进行疾病分类;75%使用计算机进行资料储存、统计分析和管理;90%以上肿瘤登记资烊用于年度报告或其它应用;70%收集和保存资料在10年以上.但开展肿瘤登记范围不大、分布不均、部分登记质量完整性差,缺乏必要的质量控制、缺乏必备及稳定的经费等支撑条件、肿瘤登记资料未充分开发利用.需进一步扩大肿瘤登记覆盖面,加强培训,进一步规范和完善我国肿瘤登记报告制度.     

Assessing Cancer Burden in Rural India : An Analysis by Cause of Death Statistics

India lacks nationwide cancer registration and systematic death registration. Gaining insight into the magnitude ‍of the cancer problem in India depends mainly on14 population based cancer registries, which provide relatively ‍accurate statistics although the area and population cover by these registries is minimal at about 7% (20% Urban ‍and 1 % Rural). With estimation of cancer burden from other sources, paucity of adequate data on the one hand ‍and the complex pathogenesis of disease on other makes for complexity in dealing with rural populations. However, ‍surveys of cause of death do reveal some interesting patterns that may very well be of use for international comparisons. ‍In this paper an attempt has been made to estimate the cancer burden in rural India using the information available ‍from surveys of cause of death for rural populations conducted by the Government of India. ‍     

2013年广西肿瘤登记地区肝癌发病与死亡分析

目的 根据2016年广西肿瘤登记地区报告资料,分析广西2013年肝癌发病和死亡情况。方法 2016年广西共有8个登记地区上报2013年肿瘤登记资料,按照全国肿瘤登记中心制定的审核方法和评价标准对数据进行评价,其中6个登记地区的数据符合标准。对入选的6个登记地区的肝癌数据进行统计分析,计算肝癌发病率、死亡率、构成比、累积率、截缩率,并按照城乡、性别、年龄、地域分层;人口标准化率根据全国2000年人口普查人口结构和Segi's世界人口结构为标准计算。结果 2013年广西肿瘤登记地区共覆盖人口5 196 871人（其中城市1 933 143人,农村3 263 728人）,新发肝癌病例数2 165例,肝癌死亡病例数1 801例。肝癌病理学诊断比例（MV%）为21.02%,只有死亡医学证明书比例（DCO%）为2.54%,死亡/发病比（M/I）为0.83。肝癌发病率为41.66/10万（男性64.07/10万,女性17.42/10万）,中标发病率为36.93/10万,世标发病率为35.92/10万,累积发病率（0～74岁）为4.01%,截缩发病率（35～64岁）为73.85/10万,在全部恶性肿瘤中的构成比为17.23%。城市地区肝癌发病率为31.19/10万,中标发病率为26.01 /10万;农村地区肝癌发病率为47.86 /10万,中标发病率为44.53 /10万。肝癌死亡率为34.66/10万（男性54.67/10万,女性13.02/10万）,中标死亡率为30.29/10万,世标死亡率为29.48/10万,累积死亡率（0～74岁）为3.23%,截缩死亡率（35～64岁）为48.12/10万,在全部恶性肿瘤中的构成比为22.77%。城市地区肝癌死亡率为22.92/10万,中标死亡率为18.96/10万。农村地区肝癌死亡率为41.61/10万,中标死亡率为37.94/10万。结论 广西肿瘤登记地区肝癌发病率、死亡率远高于全国水平,其中南部地区高于中北部地区,农村地区高于城市地区,无论城市地区或农村地区,男性发病率和死亡率均明显高于女性。     

Cancer patterns in eastern India: the first report of the Kolkata cancer registry

There are no population-based data available for the cancer patterns in Eastern India. This is the first report of cancer incidence in the region from the population-based cancer registry in Kolkata (Calcutta), the capital city of the state of West Bengal, India, for the period 1998-1999. The cancer registry collects data on all new cases of cancer diagnosed in the resident population of Kolkata. Since cancer is not a notifiable disease in India, registration is carried out by active data collection by the registry staff. The cancer registry staff visits 50 data sources comprising cancer hospitals, secondary and tertiary care hospitals, nursing homes, diagnostic laboratories and death registration offices; scrutinizes medical records and collects details on incident cancer cases. A customized version of CanReg-3 software was used for data entry and analysis. A total of 11,700 cases were registered during the 2-year period from 1 January 1998 to 31 December 1999. The overall age-adjusted (world population) incidence rates were 102.1 per 100,000 males and 114.6 per 100,000 females. The most frequently reported malignancies in males were lung cancer (16.3%), followed by cancers of the oral cavity (7.1%), pharynx (5.7%) and larynx (5.7%). In females, the most frequently reported malignancies were breast (22.7%) followed by uterine cervix (17.5%), gallbladder (6.4%) and ovary (5.8%). The data reported by the Kolkata cancer registry provide information on the cancer profile in Eastern India for the first time. The highest incidence rate of lung cancer in males in India is reported from Calcutta. A high risk of gallbladder cancer is observed in women. The observed cancer patterns indicate that tobacco-control measures and early detection of head and neck, breast and cervical cancers are of importance for cancer control in this population.     

An Independent Survey to Assess Completeness of Registration: Population Based Cancer Registry,Chennai, India

Cancer registration in the population based cancer registry (PBCR), Chennai, India, is carried out by activemethods. It undertakes re-screening of cases in government hospitals and Cancer Institute (WIA), trace back deathcertificate notifications and collect information on all the deaths, irrespective of the stated cause on the deathcertificate, occurring in the registry area routinely to reduce the under-registration of incident cancer cases andassociated mortality. The completeness of registration during 1982-95 was assessed by conducting an independentsurvey in randomly selected areas in Chennai. The total number of households covered in the survey was 7737 andwere collected which constituted 1% of the Chennai city population. The response rate to the survey was 96%. Atotal of 42,502 incident cancer cases were registered in Chennai PBCR during 1982-95. The total number of cancercases that were already registered in PBCR from the survey area during 1982-95 was 208. Out of 208 cases, 91 (44%)were identified in the survey; the families of the remaining 117 had migrated out of the surveyed area. Two newcancer cases hitherto unregistered in the PBCR during 1982-95 were identified from the survey. Based on the survey,it is estimated that the completeness of cancer registration in Chennai PBCR is 96%, which is comparable to those ofother registries in the world.     

Cancer Registration in India - Current Scenario and Future Perspectives

Cancer registration, an important component of cancer surveillance, is essential to a uni ed, scienti c and public health approach to cancer prevention and control. India has one of the highest cancer incidence and mortality rates in the world. A good surveillance system in the form of cancer registries is important for planning and evaluating cancer-control activities. Cancer registration in India was initiated in 1964 and expanded since 1982, through initiation of the National Cancer Registry Program (NCRP) by the Indian Council of Medical Research. NCRP currently has twenty-six population based registries and seven hospital based registries. Yet, Indian cancer registries, mostly in urban areas, cover less than 15% of the population. Other potential concerns about some Indian registries include accuracy and detail of information on cancer diagnosis, and timeliness in updating the registry databases. It is also important that necessary data collection related quality assurance measures be undertaken rigorously by the registries to ensure reliable and valid information availability. This paper reviews the current status of cancer registration in India and discusses some of the important pitfalls and issues related to cancer registration. Cancer registration in India should be complemented with a nationwide effort to foster systematic investigations of cancer patterns and trends by states, regions and sub populations and allow a continuous cycle of measurement, communication and action.     

Insights into cancer surveillance in Central and Eastern Europe,Israel and Turkey

The current cancer landscape within transitional economies in central and Eastern Europe and the Mediterranean area is not particularly optimistic. Current perceptions are often based on extrapolations from other countries and regions; and hence the authors collaborated with the South Eastern Europe Oncology Group (SEEROG) to collect information on cancer registration in Central and Eastern Europe, Israel and Turkey. Healthcare authorities and specialist oncology centres in 21 countries in the region were contacted for information on cancer registries in their countries. Based on this information, the authors believe that the recording and reporting of data on cancer in the region is at an acceptable level. The authors discuss and compare institution‐ and population‐based registries, and present opinions on elements of an ‘ideal registry’ based on the survey replies and comparisons with other registries. A comparison with the sources used for GLOBOCAN 2008 illustrates the need for consistent data to be communicated, published and utilised throughout the region and the oncology community. The authors conclude by considering the potential value of collaboration between health authorities across the region, as well as between the clinical and epidemiological communities, to ensure that cancer data are consistently collected, verified and made public.     

Participation of elderly patients in registration trials for oncology drug applications in Japan

Background: The objective of this study was to evaluate the age-based enrolment of cancer patients into registration trials of new drug applications or expanding the indications for use.Materials and methods: The data from 234 registration trials in Japan and overseas of 43 drugs, which were reviewed by the Pharmaceuticals and Medical Devices Agency and approved by the Ministry of Health, Labour and Welfare in Japan between 1999 and 2008, were retrospectively analyzed according to the age distribution of enrolled patients. The age distribution of the Japanese cancer population was derived from Cancer Statistics in Japan 2003 and Annual Report on Health, Labour and Welfare 2003–2004.Results: In the Japanese cancer population, the estimated median age of cancer patients is 70 years, and 66% of cancer patients are aged 65 years or more. The estimated median age of cancer patients in all registration trials conducted in Japan was 59 years, whereas it was 55 years in the registration trials conducted overseas. The proportion of patients aged 65 years or more enrolled in registration trials conducted in Japan was 35%; this number was 28% in registration trials conducted overseas.Conclusion: Elderly patients are underrepresented in oncology registration trials in Japan.     

Registration of childhood cancer: Moving towards pan-European coverage?

Cancer is relatively rare in childhood, but it contributes considerably to childhood mortality, years of life lost per person and late effects in survivors. Large populations need to be covered to set up meaningful studies of these rare conditions. Cancer registries ensure cancer surveillance, thus providing the basis for research as well as policy decisions. In this paper we examine coverage of childhood population by cancer registries in Europe and encourage national cancer registration.Over 200 cancer registries in various stages of development were identified as collecting data on childhood cancer patients in Europe. They cover 52% of the childhood population in the World Health Organisation (WHO) European region and 83% in the European Union (EU). More than 80% of this coverage is ensured by nationwide data collection, which is ongoing in 29 European countries. Overall coverage of the childhood population could increase to around 98%, if the recently established cancer registries start producing results and others improve their quality and dissemination plans. Paediatric cancer registries are being established with increasing frequency even in the areas covered by general cancer registries, and they tend to be national.Compared with regional registration, national cancer registries are more cost-effective, record larger number of cases, they can achieve higher completeness, less biased incidence and survival estimates and they are conditioned for national and international research. National registration of childhood cancer should be the rule in Europe, so that accurate regional, nation-wide and international statistics can provide solid baselines for research, clinical practice and public health policy. Governmental support and stakeholders’ involvement are indispensable to guarantee optimal data quality and completeness.     

Cancer in electrical workers: an analysis of cancer registrations in England, 1981-87.

Associations between work in the electrical and electronic industry and cancer incidence were assessed using data for 371 890 cancers registered in England between 1981 and 1987, of which 7981 were in electrical workers. Proportional registration ratios (PRRs) were calculated, both with and without the commonest cancers, with adjustment for age, social class, cancer registry of origin and sex. Of four cancers previously linked with work in the electrical and electronic industry (leukaemia, brain, breast and melanoma), only two were significantly raised: leukaemia (PRR=124, 95% CI=109-142, based on 217 cases) and malignant brain cancer (PRR=118, 95% CI=103-136, based on 204 cases). A significantly increased risk was also observed for pleural cancer (PRR=201, 95% CI=167-241, based on 115 cases). The histology of almost 90% of pleural cancers was coded as mesothelioma, confirming the previously observed association between pleural cancer and exposure to asbestos in electrical workers. The extent to which workplace exposures to extremely low frequency electromagnetic fields explains the excesses seen here for leukaemia and brain cancer requires further study.     

内蒙古2016年食管癌发病和死亡现状及2012-2016年趋势分析

目的 分析内蒙古肿瘤登记地区2016年食管癌发病和死亡现状及2012—2016年流行趋势.方法 收集2012—2016年内蒙古肿瘤登记地区食管癌数据,按照城乡、性别及年龄别分层,计算食管癌的发病(死亡)粗率、标化率、累积率、年龄别率、年度变化百分比(Annual percentage change,APC).结果 20...     

Development of Population-based Cancer Mortality Registration in the North of Viet Nam

Background: Regional cancer distributions provide useful pointers to potential environmental risk factors. Cancerdeath registration data are also basic for checking completeness of population-based registration of cancer incidence.The aim of the present project was to develop population-based cancer mortality registration in various regions inthe North of Viet Nam. Methods: Cancer data were accessed from the database of population-routine-based deathregistration performed by medical workers at commune health stations based on the guidelines of the Ministry ofHealth. All deaths occurring in the communities were registered and the registration process was monthly reviewedfor each fatal case regarding the name, age, sex, address, occupation, date - place - cause of death, and informationconcerning to pre-death medical care during the study period from 1999 to 2005. The list of deaths and residents ofthe study population were carefully cross-checked with other information sources to avoid under or over registration.The study sites were Red River Delta areas and a high-mountain area. The world population structure was used toestimate age-standardized cancer mortality rates per 100,000 (ASR). Results: During 4,330,620 person-years estimatedduring 1999 to 2005, 21,108 deaths were registered. The crude death rate from all causes was 487.4 / 100,000. Amongthem, 4,244 cancers in all sites (2,835 in males and 1,409 in females) were registered, giving mortality rates / 100,000of 134.6 and 63.3 (crude), and 155.7 and 54.3 (ASR), for males and females, respectively. The rate for the highmountainarea was only half (45.5) those in the Red River Delta (95.2-117.4). Male to female ratios were ranked from2.2 to 3.1. Cancer accounted for about 20% of all causes of death. Conclusions: The present findings suggest that inViet Nam, development of reliable population-based cancer mortality registration is feasible and practical.     

2000~2009年浙江省肿瘤登记地区子宫体癌发病与死亡分析

[目的]分析浙江省肿瘤登记地区2000～2009年子宫体癌的发病与死亡情况。[方法]数据来源于浙江省6个肿瘤登记处上报于浙江省肿瘤防治办公室的肿瘤发病和死亡资料．分别计算发病（死亡）例数、粗发病率（死亡率）、构成比、中标率、世标率、累积率、截缩率以及年度变化百分比等指标。[结果]2000—2009年浙江省6个肿瘤登记地区共计报告子宫体癌新发病例2347例,占女性癌症新发病例的3-35％。子宫体癌发病率为7．92／10万,中标率为4．64／10万,位居女性癌症发病顺位的第9位。子宫体癌发病率呈总体增长趋势,从2000年的5．13／10万增长到2009年的8．69／10万,年度变化百分比（APC）为6．40％（95％CI：3．78％～9．08％）。2000～2009年共报告子宫体癌死亡病例854例,占女性癌症死亡病例的2．56％。子宫体癌死亡率为2．88／10万,中标率为1．41／10万,居女性癌症死因顺位的第11位。子宫体癌死亡率呈现波动增长趋势,年度变化百分比为5．84％（95％CI：-2．70％～15．13％）。[结论]浙江省子宫体癌发病和死亡呈上升趋势,应加强肿瘤防治等措施．以期降低子宫体癌的发病水平。     

Staging quality is related to the survival of women with endometrial cancer: a Scottish population based study. Deficient surgical staging and omission of adjuvant radiotherapy is associated with poorer survival of women diagnosed with endometrial cancer in Scotland during 1996 and 1997

The association between treatment variation and survival of women with endometrial cancer was investigated. A retrospective cohort based upon the complete Scottish population registered on in-patient and day-case hospital discharge data (Scottish Morbidity Record-1) and cancer registration (Scottish Morbidity Record-6) coded C54 and C55 in ICD10, between 1st January 1996 to 31st December 1997 were analysed. Seven hundred and three patients who underwent surgical treatment out of 781 patients that were diagnosed with endometrial cancer in Scotland during 1996 and 1997. The overall quality of surgical staging was poor. The quality of staging was related to both the year that the surgeon passed the Member of the Royal College of Obstetricians and Gynaecologists examination and also to 'specialist' status but was not related to surgeon caseload. Two clinically important prognostic factors were found to be associated with survival; whether the International Federation of Obstetrics and Gynaecology stage was documented, RHR=2.0 (95% CI=1.3 to 3.1) and also to the use of adjuvant radiotherapy, RHR=2.2 (95% CI=1.5 to 3.5). The associations with survival were strongest in patients with advanced disease, International Federation of Obstetrics and Gynaecology stages 1C through to stage 3. Deficiencies in staging and variations in the use of adjuvant radiotherapy represent a possible source of avoidable mortality in patients with endometrial cancer. Consequently, there should be a greater emphasis on improving the overall quality of surgical staging in endometrial cancer.     

2014年广西肿瘤登记地区结直肠肛门癌发病和死亡分析

目的  分析2014年广西结直肠肛门癌发病和死亡情况。方法  按照全国肿瘤登记中心制定的审核方法和评价标准评估广西肿瘤登记地区上报的2014年肿瘤登记数据,将9个入选的肿瘤登记地区的肿瘤发病、死亡和人口数据进行汇总,按地区（城乡）、性别、年龄别分层,计算结直肠肛门癌的发病率、死亡率、构成比和截缩率等。人口标准化率根据2000年全国人口普查结构和Segis′s世界人口结构。结果  2014年广西纳入分析的9个肿瘤登记地区结直肠肛门癌新发病例为1 716例（其中男性1 039例,女性677例）,发病率为24.74/10万,中标率为19.68 /10万,世标率为19.37/10万,男性发病率高于女性（28.73% vs 20.40%,χ²=48.433,P<0.001）;城市地区发病率为36.19/10万,中标率为27.45/10万;农村地区发病率为19.24/10万,中标率为16.07/10万。结直肠肛门癌死亡病例827例（其中男性518例,女性309例）,死亡率为11.93/10万,中标率为9.06/10万,世标率为9.00 /10万,男性死亡率高于女性（14.32% vs 9.31%,χ²=36.400,P<0.001）;城市地区死亡率为17.63/10万,中标率为13.21/10万;农村地区死亡率为9.18/10万,中标率为7.13/10万。结论  广西肿瘤登记地区结直肠肛门癌发病和死亡例数男性均高于女性,城市地区高于农村地区,45岁以上的中老年人群尤其是城市地区男性人群是重点开展肿瘤防治工作的对象。     

安徽省肿瘤登记地区2015年胃癌发病与死亡

目的 分析安徽省肿瘤登记地区2015年胃癌的发病和死亡情况,为制定胃癌防治措施提供基础数据。方法 经过质量审核后,22个肿瘤登记处数据被纳入分析,按照地区(城乡)、性别分层计算胃癌发病率、死亡率,采用2000年中国标准人口和Segi′s世界人口构成分别计算中国人口和世界人口年龄标化发病/死亡率。结果 安徽省肿瘤登记地区报告胃癌新发病例9 383例,死亡病例6 681例。全省胃癌死亡发病比(M/I)为0.71,病理诊断率(MV%)为64.19%,只有死亡让明书比例(DCO%)为2.59%。安徽省肿瘤登记地区2015年胃癌发病粗率为43.85/10万(男性60.94/10万,女性25.78/10万),中国人口标化率为30.99/10万,世界人口标化率为30.86/10万;城市地区发病粗率为35.82/10万,中国人口标化率为25.00/10万;农村地区发病粗率为49.79/10万,中国人口标化率为35.52/10万。安徽省肿瘤登记地区2015年胃癌死亡粗率为31.22/10万(男性43.74/10万,女性17.99/10万),中国人口标化率为21.33/10万,世界人口标化率为21.04/10万;城市地区死亡粗率为25.55/10万,中国人口标化率为17.25/10万;农村地区死亡粗率为20.51/10万,中国人口标化率为24.44/10万。结论 必须将农村人口以及男性人口作为胃癌防治的重点对象,推进上消化道癌的早诊早治,提高早期胃癌的检出率,减少胃癌发病与死亡造成的疾病负担。